{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:08:55Z","timestamp":1770433735971,"version":"3.49.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1007\/s11899-006-0004-9","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T05:24:49Z","timestamp":1180070689000},"page":"230-240","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of Burkitt lymphoma in children and adults: Lessons from Africa"],"prefix":"10.1007","volume":"1","author":[{"given":"Ian T.","family":"Magrath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"4_CR1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/bjs.18004619704","volume":"46","author":"D Burkitt","year":"1958","unstructured":"Burkitt D: A sarcoma involving the jaws in African children. Brit J Surg 1958, 46:218\u2013223.","journal-title":"Brit J Surg"},{"key":"4_CR2","doi-asserted-by":"crossref","unstructured":"National Cancer Institute sponsored study of classifications of non-Hodgkin\u2019s lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin\u2019s Lymphoma Pathologic Classification Project. Cancer 1982, 49:2112\u20132135.","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"4_CR3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.1991.9.2.211","volume":"9","author":"B Coiffier","year":"1991","unstructured":"Coiffier B, Gisselbrecht C, Vose JM, et al.: Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 1991, 9:211\u2013219.","journal-title":"J Clin Oncol"},{"key":"4_CR4","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood.V83.6.1460.1460","volume":"83","author":"TP Miller","year":"1994","unstructured":"Miller TP, Grogan TM, Dahlberg S, et al.: Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin\u2019s lymphomas: a prospective Southwest Oncology Group trial. Blood 1994, 83:1460\u20131466.","journal-title":"Blood"},{"key":"4_CR5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0145-2126(80)90045-4","volume":"4","author":"IT Magrath","year":"1980","unstructured":"Magrath IT, Ziegler JL: Bone marrow involvement in Burkitt\u2019s lymphoma and its relationship to acute B-cell leukemia. Leukemia Res 1980, 4:33\u201359.","journal-title":"Leukemia Res"},{"key":"4_CR6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495","volume":"87","author":"D Hoelzer","year":"1996","unstructured":"Hoelzer D, Ludwig W-D, Thiel E, et al.: Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996, 87:495\u2013508.","journal-title":"Blood"},{"key":"4_CR7","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1182\/blood-2004-02-0405","volume":"104","author":"K Blum","year":"2004","unstructured":"Blum K, Lozanski G, Byrd JC: Adult Burkitt leukemia and lymphoma. Blood 2004, 104:3009\u20133020. Excellent review of pathogenesis and treatment.","journal-title":"Blood"},{"key":"4_CR8","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJM198303103081003","volume":"308","author":"JR Anderson","year":"1983","unstructured":"Anderson JR, Wilson JF, Jenkin DT, et al.: Childhood non-Hodgkin\u2019s lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med 1983, 308:559\u2013565.","journal-title":"N Engl J Med"},{"key":"4_CR9","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1200\/JCO.1993.11.6.1024","volume":"11","author":"JR Anderson","year":"1993","unstructured":"Anderson JR, Jenkin RD, Wilson JF, et al.: Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin\u2019s lymphoma: a report of CCG-551 from the Children\u2019s Cancer Group. J Clin Oncol 1993, 11:1024\u20131032.","journal-title":"J Clin Oncol"},{"key":"4_CR10","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","volume":"14","author":"I Magrath","year":"1996","unstructured":"Magrath I, Adde M, Shad A, et al.: Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996, 14:925\u2013934.","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"4_CR11","first-page":"33","volume":"25","author":"M Adde","year":"1998","unstructured":"Adde M, Shad A, Venzon D, et al.: Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Semin Oncol 1998, 25(2 Suppl 4):33\u201339.","journal-title":"Semin Oncol"},{"key":"4_CR12","first-page":"3294","volume":"94","author":"A Reiter","year":"1999","unstructured":"Reiter A, Schrappe M, Tiemann M, et al.: Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-M\u00fcnster Group Trial NHL-BFM 90. Blood 1999, 94:3294\u20133306.","journal-title":"Blood"},{"key":"4_CR13","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","volume":"97","author":"C Patte","year":"2001","unstructured":"Patte C, Auperin A, Michon J, et al.; on behalf of the Soci\u2019et\u2019e Fran\u00e7aise d\u2019Oncologie P\u2019ediatrique: The Soci\u2019et\u2019e Fran\u00c7aise d\u2019Oncologie P\u2019ediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001, 97:3370\u20133379.","journal-title":"Blood"},{"key":"4_CR14","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1200\/JCO.2002.08.088","volume":"20","author":"F Spreafico","year":"2002","unstructured":"Spreafico F, Massimino M, Luksch R, et al.: Intensive, very short-term chemotherapy for advanced Burkitt\u2019s lymphoma in children. J Clin Oncol 2002, 20:2783\u20132788.","journal-title":"J Clin Oncol"},{"key":"4_CR15","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1200\/JCO.1999.17.8.2461","volume":"17","author":"DA Thomas","year":"1999","unstructured":"Thomas DA, Cortes J, O\u2019Brien S, et al.: Hyper-CVAD program in Burkitt\u2019s-type adult acute lymphoblastic leukemia. J Clin Oncol 1999, 17:2461\u20132470.","journal-title":"J Clin Oncol"},{"key":"4_CR16","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1200\/JCO.2001.19.20.4014","volume":"19","author":"EJ Lee","year":"2001","unstructured":"Lee EJ, Petroni GR, Schiffer CA, et al.: Brief-duration highintensity chemotherapy for patients with small noncleaved cell lymphoma or FAB L3 acute lymphocytic leukemia: results of Cancer and Leukemia Group B Study 9251. J Clin Oncol 2001, 19:4014\u20134022.","journal-title":"J Clin Oncol"},{"key":"4_CR17","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.1996.14.9.2465","volume":"14","author":"JW Sweetenham","year":"1996","unstructured":"Sweetenham JW, Pearce R, Taghipour G, et al.: Adult Burkitt\u2019s and Burkitt-like non-Hodgkin\u2019s lymphoma\u2014outcome for patients treated with high-dose therapy and autologous stemcell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol 1996, 14:2465\u20132472.","journal-title":"J Clin Oncol"},{"key":"4_CR18","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","volume":"13","author":"GM Mead","year":"2002","unstructured":"Mead GM, Sydes MR, Walewski J, et al.; on behalf of the UKLG LY06 collaborators: An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt\u2019s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002, 13:1264\u20131274.","journal-title":"Ann Oncol"},{"key":"4_CR19","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/1042819031000141301","volume":"45","author":"A Lacasce","year":"2004","unstructured":"Lacasce A, Howard O, Lib S, et al.: Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma 2004, 45:761\u2013767. Results in adults with a higher median age (47), using a protocol described in references 10 and 11.","journal-title":"Leuk Lymphoma"},{"key":"4_CR20","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V85.3.664.bloodjournal853664","volume":"85","author":"C Soussain","year":"1995","unstructured":"Soussain C, Patte C, Ostronoff M, et al.: Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 1995, 85:664\u2013674.","journal-title":"Blood"},{"key":"4_CR21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF01703945","volume":"65","author":"HW Pees","year":"1992","unstructured":"Pees HW, Radtke H, Schwamborn J, Graf N: The BFMprotocol for HIV-negative Burkitt\u2019s lymphomas and L3 ALL in adult patients: a high chance for cure. Ann Hematol 1992, 65:201\u2013205.","journal-title":"Ann Hematol"},{"key":"4_CR22","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/cncr.11628","volume":"98","author":"ES Wang","year":"2003","unstructured":"Wang ES, Straus DJ, Teruya-Feldstein J, et al.: Intensive chemotherapy with cyclophosphamide, doxorubicin, highdose methotrexate\/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M\/IVAC) for human immunode. Efficiency virus-associated Burkitt lymphoma. Cancer 2003, 98:1196\u20131205. Tolerance of a high-intensity protocol in patients with HIV-associated Burkitt lymphoma.","journal-title":"Cancer"},{"key":"4_CR23","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00043426-199122000-00019","volume":"13","author":"IT Magrath","year":"1991","unstructured":"Magrath IT: African Burkitt\u2019s lymphoma. History, biology, clinical features, and treatment. Am J Pediatr Hematol Oncol 1991, 13:222\u2013246.","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"4_CR24","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1182\/blood-2003-08-2986","volume":"102","author":"MA Karajannis","year":"2003","unstructured":"Karajannis MA, Hummel M, Oschlies I, et al.: Epstein-Barr virus infection in Western European pediatric non-Hodgkin lymphomas [letter]. Blood 2003, 102:4244.","journal-title":"Blood"},{"key":"4_CR25","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/1097-0142(1967)20:5<756::AID-CNCR2820200530>3.0.CO;2-P","volume":"20","author":"D Burkitt","year":"1967","unstructured":"Burkitt D: Long term remissions following one and two dose chemotherapy for African lymphoma. Cancer 1967, 20:756.","journal-title":"Cancer"},{"key":"4_CR26","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/1097-0142(19800315)45:6<1507::AID-CNCR2820450634>3.0.CO;2-D","volume":"45","author":"I Magrath","year":"1980","unstructured":"Magrath I, Lee YJ, Anderson T, et al.: Prognostic factors in Burkitt\u2019s lymphoma: importance of total tumor burden. Cancer 1980, 45:1507\u20131515.","journal-title":"Cancer"},{"key":"4_CR27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/bmj.4.5575.323","volume":"4","author":"RH Morrow","year":"1967","unstructured":"Morrow RH, Pike MC, Kisuule A: Survival of Burkitt\u2019s lymphoma patients in Mulago Hospital, Uganda. Br Med J 1967, 4:323\u2013327.","journal-title":"Br Med J"},{"key":"4_CR28","first-page":"297","volume":"20","author":"PJ Fialkow","year":"1977","unstructured":"Fialkow PJ: Glucose-6-phosphate dehydrogenase (G-6-PD) markers in Burkitt lymphoma and other malignancies. Haematol Blood Transfus 1977, 20:297\u2013305.","journal-title":"Haematol Blood Transfus"},{"key":"4_CR29","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1182\/blood.V72.2.792.792","volume":"72","author":"F Barriga","year":"1988","unstructured":"Barriga F, Whang-Peng J, Lee E, et al.: Development of a second clonally discrete Burkitt\u2019s lymphoma in a human immunodeficiency virus-positive homosexual patient. Blood 1988, 72:792\u2013795.","journal-title":"Blood"},{"key":"4_CR30","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1001\/jama.1972.03210090046017","volume":"222","author":"VA Ngu","year":"1972","unstructured":"Ngu VA: Chemotherapy of Burkitt\u2019s tumor at the University of Ibadan, Nigeria. JAMA 1972, 222:1166.","journal-title":"JAMA"},{"key":"4_CR31","first-page":"2578","volume":"27","author":"P Clifford","year":"1967","unstructured":"Clifford P: Long term survival of patients with Burkitt\u2019s lymphoma. An assessment of treatment and other factors which may relate to survival. Cancer Res 1967, 27:2578.","journal-title":"Cancer Res"},{"key":"4_CR32","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/1097-0142(197008)26:2<474::AID-CNCR2820260232>3.0.CO;2-A","volume":"26","author":"JL Ziegler","year":"1970","unstructured":"Ziegler JL, Morrow RH Jr, Fass L, et al.: Treatment of Burkitt\u2019s tumor with cyclophosphamide. Cancer 1970, 26:474\u2013484.","journal-title":"Cancer"},{"key":"4_CR33","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ijc.2910100205","volume":"10","author":"JL Ziegler","year":"1972","unstructured":"Ziegler JL, Bluming AZ, Magrath IT, Carbone PP: Intensive chemotherapy in patients with generalized Burkitt\u2019s lymphoma. Int J Cancer 1972, 10:254\u2013261.","journal-title":"Int J Cancer"},{"key":"4_CR34","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/bmj.3.5773.508","volume":"3","author":"JL Ziegler","year":"1971","unstructured":"Ziegler JL, Bluming AZ: Intrathecal chemotherapy in Burkitt\u2019s lymphoma. Br Med J 1971, 3:508\u2013512.","journal-title":"Br Med J"},{"key":"4_CR35","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.1991.9.11.1973","volume":"9","author":"TB Haddy","year":"1991","unstructured":"Haddy TB, Adde MA, Magrath IT: CNS involvement in small noncleaved-cell lymphoma: is CNS disease per se a poor prognostic sign? J Clin Oncol 1991, 9:1973\u20131982.","journal-title":"J Clin Oncol"},{"key":"4_CR36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/02841867709133941","volume":"16","author":"CL Olweny","year":"1977","unstructured":"Olweny CL, Atine I, Kaddu-Mukasa A, et al.: Cerebrospinal irradiation of Burkitt\u2019s lymphoma. Failure in preventing central nervous system relapse. Acta Radiol Ther Phys Biol 1977, 16:225\u2013231.","journal-title":"Acta Radiol Ther Phys Biol"},{"key":"4_CR37","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ijc.2910170404","volume":"17","author":"CL Olweny","year":"1976","unstructured":"Olweny CL, Katongole-Mbidde E, Kaddu-Mukasa A, et al.: Treatment of Burkitt\u2019s lymphoma: randomized clinical trial of single-agent versus combination chemotherapy. Int J Cancer 1976, 17:436\u2013440.","journal-title":"Int J Cancer"},{"key":"4_CR38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/ijc.2910260302","volume":"26","author":"CL Olweny","year":"1980","unstructured":"Olweny CL, Katongole-Mbidde E, Otim D, et al.: Longterm experience with Burkitt\u2019s lymphoma in Uganda. Int J Cancer 1980, 26:261\u2013266.","journal-title":"Int J Cancer"},{"key":"4_CR39","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/0002-9343(75)90597-5","volume":"58","author":"JC Arseneau","year":"1975","unstructured":"Arseneau JC, Canellos GP, Banks PM, et al.: American Burkitt\u2019s lymphoma: a clinicopathologic study of 30 cases. I. Clinical factors relating to prolonged survival. Am J Med 1975, 58:314\u2013321.","journal-title":"Am J Med"},{"key":"4_CR40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1056\/NEJM197707142970202","volume":"297","author":"JL Ziegler","year":"1977","unstructured":"Ziegler JL: Treatment results of 54 American patients with Burkitt\u2019s lymphoma are similar to the African experience. N Engl J Med 1977, 297:75\u201380.","journal-title":"N Engl J Med"},{"key":"4_CR41","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/1097-0142(197803)41:3<1059::AID-CNCR2820410339>3.0.CO;2-N","volume":"41","author":"FR Appelbaum","year":"1978","unstructured":"Appelbaum FR, Deisseroth AB, Graw RG Jr, et al.: Prolonged complete remission following high dose chemotherapy of Burkitt\u2019s lymphoma in relapse. Cancer 1978, 41:1059\u20131063.","journal-title":"Cancer"},{"key":"4_CR42","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2141.2004.05141.x","volume":"126","author":"M Nicola Di","year":"2004","unstructured":"Di Nicola M, Carlo-Stella C, Mariotti J, et al.: High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt\u2019s lymphoma in adults. Brit J Haematol 2004, 126:815\u2013820.","journal-title":"Brit J Haematol"},{"key":"4_CR43","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/sj.leu.2403733","volume":"19","author":"GW Imhoff van","year":"2005","unstructured":"van Imhoff GW, van der Holt B, MacKenzie MA, et al.: Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON): Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia 2005, 19:945\u2013952.","journal-title":"Leukemia"},{"key":"4_CR44","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/cncr.20143","volume":"100","author":"DA Rizzieri","year":"2004","unstructured":"Rizzieri DA, Johnson JL, Niedzwiecki D, et al.: Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer 2004, 100:1438\u20131448.","journal-title":"Cancer"},{"key":"4_CR45","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/1097-0142(197609)38:3<1043::AID-CNCR2820380302>3.0.CO;2-U","volume":"38","author":"I Djerassi","year":"1976","unstructured":"Djerassi I, Kim JS: Methotrexate and citrovorum factor rescue in the management of childhood lymphosarcoma and reticulum cell sarcoma (non-Hodgkin\u2019s lymphomas): prolonged unmaintained remissions. Cancer 1976, 38:1043\u20131051.","journal-title":"Cancer"},{"key":"4_CR46","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/blood.V63.5.1102.1102","volume":"63","author":"IT Magrath","year":"1984","unstructured":"Magrath IT, Janus C, Edwards BK, et al.: An effective therapy for both undifferentiated (including Burkitt\u2019s) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 1984, 63:1102\u20131111.","journal-title":"Blood"},{"key":"4_CR47","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.1986.4.12.1732","volume":"4","author":"SB Murphy","year":"1986","unstructured":"Murphy SB, Bowman WP, Abromowitch M, et al.: Results of treatment of advanced-stage Burkitt\u2019s lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated highdose methotrexate and cytarabine. J Clin Oncol 1986, 4:1732\u20131739.","journal-title":"J Clin Oncol"},{"key":"4_CR48","first-page":"126","volume":"9","author":"H Gadner","year":"1986","unstructured":"Gadner H, Muller-Weihrich S, Riehm H: [Treatment strategies in malignant non-Hodgkin lymphomas in childhood] [German]. Onkologie 1986, 9:126\u2013130.","journal-title":"Onkologie"},{"key":"4_CR49","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.1991.9.1.133","volume":"9","author":"MR Schwenn","year":"1991","unstructured":"Schwenn MR, Blattner SR, Lynch E, Weinstein HJ: HiCCOM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt\u2019s lymphoma and B-cell acute lymphoblastic leukemia. J Clin Oncol 1991, 9:133\u2013138.","journal-title":"J Clin Oncol"},{"key":"4_CR50","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-03-0973","volume":"105","author":"W Woessmann","year":"2005","unstructured":"Woessmann W, Seidemann K, Mann G, et al.: BFM Group: The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHLBFM95. Blood 2005, 105:948\u2013958. Speaks to the importance of methotrexate in children with Burkitt lymphoma.","journal-title":"Blood"},{"key":"4_CR51","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bjc.6601472","volume":"90","author":"AJ Ferreri","year":"2004","unstructured":"Ferreri AJ, Guerra E, Regazzi M: Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 2004, 90:353\u2013358. Speaks to the importance and tolerance of high-dose methotrexate in adults with primary central nervous system lymphomas.","journal-title":"Br J Cancer"},{"key":"4_CR52","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.1996.14.1.240","volume":"14","author":"M Divine","year":"1996","unstructured":"Divine M, Lepage E, Briere J, et al.: Is the small noncleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol 1996, 14:240\u2013248.","journal-title":"J Clin Oncol"},{"key":"4_CR53","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/oxfordjournals.annonc.a059214","volume":"6","author":"LM Jost","year":"1995","unstructured":"Jost LM, Jacky E, Dommann-Scherrer C, et al.: Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt\u2019s lymphomas in adult patients. Ann Oncol 1995, 6:445\u2013451.","journal-title":"Ann Oncol"},{"key":"4_CR54","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/mpo.1226","volume":"37","author":"R Sposto","year":"2001","unstructured":"Sposto R, Meadows AT, Chilcote RR, et al.: Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: a report from the Children\u2019s Cancer Group. Med Pediatr Oncol 2001, 37:432\u2013441.","journal-title":"Med Pediatr Oncol"},{"key":"4_CR55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/08880018609031196","volume":"3","author":"C Patte","year":"1986","unstructured":"Patte C, Bernard A, Hartmann O, et al.: High-dose methotrexate and continuous infusion Ara-C in children\u2019s non-Hodgkin\u2019s lymphoma: phase II studies and their use in further protocols. Pediatr Hematol Oncol 1986, 3:11\u201318.","journal-title":"Pediatr Hematol Oncol"},{"key":"4_CR56","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.1990.8.4.661","volume":"8","author":"JC Gentet","year":"1990","unstructured":"Gentet JC, Patte C, Quintana E: Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin\u2019s lymphoma: a study of the French Society of Pediatric Oncology. J Clin Oncol 1990, 8:661\u2013665.","journal-title":"J Clin Oncol"},{"key":"4_CR57","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/hon.2900090413","volume":"9","author":"I Magrath","year":"1991","unstructured":"Magrath I, Adde M, Sandlund J, Jain V: Ifosfamide in the treatment of high-grade recurrent non-Hodgkin\u2019s lymphomas. Hematol Oncol 1991, 9:267\u2013274.","journal-title":"Hematol Oncol"},{"issue":"Suppl 1","key":"4_CR58","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/annonc\/8.suppl_1.S77","volume":"8","author":"G Todeschini","year":"1997","unstructured":"Todeschini G, Tecchio C, Degani D, et al.: Eighty-one percent event-free survival in advanced Burkitt\u2019s lymphoma\/ leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol. Ann Oncol 1997, 8(Suppl 1):77\u201381.","journal-title":"Ann Oncol"},{"key":"4_CR59","first-page":"1809","volume-title":"Oxford Textbook of Oncology.","author":"I Magrath","year":"1995","unstructured":"Magrath I: The non-Hodgkin\u2019s lymphomas in children. In Oxford Textbook of Oncology. Edited by Peckham MJ, Veronesi U, Pinedo HM. Oxford: Oxford Medical Publications; 1995:1809\u20131851."},{"key":"4_CR60","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1385\/MO:22:3:257","volume":"22","author":"JA Sparano","year":"2005","unstructured":"Sparano JA, Negassa A, Lansigan E, et al.: Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin\u2019s lymphoma. Med Oncol 2005, 22:257\u2013268. Speaks to role of colony-stimulating factors in increasing dose density.","journal-title":"Med Oncol"},{"key":"4_CR61","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/annonc\/mdh113","volume":"15","author":"G Todeschini","year":"2004","unstructured":"Todeschini G, Gelio S, Tecchio C: Rituximab-CHOP or two-weekly CHOP + G-CSF in aggressive lymphoma of the elderly? Ann Oncol 2004, 15:538\u2013539.","journal-title":"Ann Oncol"},{"key":"4_CR62","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/01.pas.0000168176.71405.e5","volume":"29","author":"E Haralambieva","year":"2005","unstructured":"Haralambieva E, Boerma EJ, van Imhoff GW, et al.: Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surg Pathol 2005, 29:1086\u20131094. Addresses the issue of lymphomas intermediate in morphology between Burkitt lymphoma and diffuse large-B-cell lymphomas (DLBCLs).","journal-title":"Am J Surg Pathol"},{"key":"4_CR63","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa055351","volume":"354","author":"M Hummel","year":"2006","unstructured":"Hummel M, Bentink S, Berger H, et al.: A biologic definition of Burkitt\u2019s lymphoma from transcriptional and genomic profiling. N Engl J Med 2006, 354:2419\u20132430. Provides new information on the molecular profile of BL, BLL, and DLBCL.","journal-title":"N Engl J Med"},{"key":"4_CR64","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","volume":"354","author":"SS Dave","year":"2006","unstructured":"Dave SS, Fu K, Wright GW, et al.; for the Lymphoma\/Leukemia Molecular Profiling Project: Molecular diagnosis of Burkitt\u2019s lymphoma. N Engl J Med 2006, 354:2431\u20132442. Provides new information on the molecular profiling of BL, BLL, and DLBCL.","journal-title":"N Engl J Med"},{"key":"4_CR65","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"N Harris","year":"1994","unstructured":"Harris N, Jaffe E, Stein H, et al.: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361\u20131392.","journal-title":"Blood"},{"key":"4_CR66","volume-title":"World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues","year":"2001","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001."},{"key":"4_CR67","doi-asserted-by":"crossref","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project. Blood 1997, 89:3909\u20133918.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"4_CR68","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","volume":"17","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J, et al.: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting\u2014Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17:3835\u20133849.","journal-title":"J Clin Oncol"},{"key":"4_CR69","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1182\/blood.V97.12.3713","volume":"97","author":"RM Braziel","year":"2001","unstructured":"Braziel RM, Arber DA, Slovak ML: The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. Blood 2001, 97:3713\u20133720.","journal-title":"Blood"},{"key":"4_CR70","doi-asserted-by":"crossref","first-page":"210","DOI":"10.5858\/2004-128-210-FLWABT","volume":"128","author":"PM Voorhees","year":"2004","unstructured":"Voorhees PM, Carder KA, Smith SV, et al.: Follicular lymphoma with a Burkitt translocation\u2014predictor of an aggressive clinical course: a case report and review of the literature. Arch Pathol Lab Med 2004, 128:210\u2013213.","journal-title":"Arch Pathol Lab Med"},{"key":"4_CR71","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/sj.leu.2403661","volume":"19","author":"S Knezevich","year":"2005","unstructured":"Knezevich S, Ludkovski O, Salski C, et al.: Concurrent translocation of BCL2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas. Leukemia 2005, 19:659\u2013663.","journal-title":"Leukemia"},{"key":"4_CR72","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503\u2013511.","journal-title":"Nature"},{"key":"4_CR73","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, et al.: Lymphoma\/Leukemia Molecular Profiling Project: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937\u20131947.","journal-title":"N Engl J Med"},{"key":"4_CR74","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2005-10-4213","volume":"107","author":"I Oschlies","year":"2006","unstructured":"Oschlies I, Klapper W, Zimmermann M, et al.: Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood 2006, 107:4047\u20134052. Demonstration of germinal-center cell origin of childhood DLBCL.","journal-title":"Blood"},{"key":"4_CR75","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cancergencyto.2004.01.008","volume":"153","author":"BJ Dave","year":"2004","unstructured":"Dave BJ, Weisenburger DD, Higgins CM, et al.: Cytogenetics and fiuorescence in situ hybridization studies of diffuse large B-cell lymphoma in children and young adults. Cancer Genet Cytogenet 2004, 153:115\u2013121.","journal-title":"Cancer Genet Cytogenet"},{"key":"4_CR76","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/annonc\/mdi075","volume":"16","author":"K Jahnke","year":"2005","unstructured":"Jahnke K, Korfel A, Martus P, et al.; on behalf of the German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG): High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 2005, 16:445\u2013449. Speaks to tolerance of high-dose methotrexate in elderly patients.","journal-title":"Ann Oncol"},{"key":"4_CR77","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/cncr.10241","volume":"94","author":"MA Weiser","year":"2002","unstructured":"Weiser MA, O\u2019Brien S, Thomas DA, et al.: Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen. Cancer 2002, 94:285\u2013291.","journal-title":"Cancer"},{"key":"4_CR78","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdi403","volume":"16","author":"M Divine","year":"2005","unstructured":"Divine M, Casassus P, Koscielny S, et al.: GELA; GOELAMS: Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol 2005, 16:1928\u20131935. Provides information on the response of adults with BL to the LMB protocol designed for children and demonstrates the value of a risk-adapted approach.","journal-title":"Ann Oncol"},{"key":"4_CR79","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","volume":"106","author":"DA Thomas","year":"2006","unstructured":"Thomas DA, Faderl S, O\u2019Brien S, et al.: Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006, 106:1569\u20131580. Provides information regarding the value of rituximab in the context of a high-intensity protocol for BL in adults.","journal-title":"Cancer"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-006-0004-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-006-0004-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-006-0004-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T05:36:27Z","timestamp":1628919387000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-006-0004-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["4"],"URL":"https:\/\/doi.org\/10.1007\/s11899-006-0004-9","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}